Use of Early Remdesivir to Prevent Progression of COVID-19 to Severe Disease When Given in the Outpatient Setting
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Take it with you! CLL Society’s Official COVID-19 Triage Statement
CLL Society has authored an Official Statement to help you help your healthcare providers understand CLL patients’ unique vulnerabilities to COVID-19 and our higher risks of serious complications.
This letter to your healthcare provider may help you be attended to faster, should you have any COVID-19 symptoms or worries. It also reminds providers of the possible benefits of timely administration of one of the authorized SARS-CoV-2 monoclonal antibodies to prevent serious illness or hospitalization, or the early use of high titer convalescent plasma in hospital.
COVID-19 concerns are topline in medical settings these days and the demands for care can overwhelm some medical facilities, so triaging who gets attention and more intensive management becomes a necessity. Fax, email, or otherwise draw your provider’s attention to this letter!
The CLL Society is invested in your long life. Please invest in the long life of the CLL Society.
Updated: 7/16/2021.
Related posts
